Exact Mass: 417.20925320000003
Exact Mass Matches: 417.20925320000003
Found 500 metabolites which its exact mass value is equals to given mass value 417.20925320000003
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Cilazapril
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
Cilazapril
Cilazapril is only found in individuals that have used or taken this drug. It is one of the angiotensin-converting enzyme inhibitors (ACE inhibitors) used for hypertension. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. [PubChem]Cilazapri, as a pyridazine ACE inhibitor, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. As angiotensin II is a vasoconstrictor and a negative feedback mediator for renin activity, lower angiotensin II levels results in a decrease in blood pressure, an increase in renin activity, and stimulation of baroreceptor reflex mechanisms. Kininase II, an enzyme which degrades the vasodilator bradykinin, is identical to ACE and may also be inhibited. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one
C25H27N3O3 (417.20523120000007)
Cinepazide
Ethyl 3-((6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoate
Protostemonine
Protostemonine is an alkaloid. It has a role as a metabolite. Protostemonine is a natural product found in Stemona cochinchinensis, Stemona pierrei, and other organisms with data available. A natural product found particularly in Stemona and Stemona.
3alpha,6beta-dicinnamoyloxytropane
C26H27NO4 (417.19399820000007)
Hexanoic acid, 2-hydroxy-2-((phenylamino)carbonyl)-, 1,2-diphenylhydrazide
C25H27N3O3 (417.20523120000007)
(-)-8beta-(4-hydroxybenzyl)-2,3-dimethoxyberbin-10-ol
C26H27NO4 (417.19399820000007)
Ala Glu Lys Ala
Ala Ala Ala Trp
C20H27N5O5 (417.20120920000005)
Ala Ala Glu Lys
Ala Ala Lys Glu
Ala Ala Trp Ala
C20H27N5O5 (417.20120920000005)
Ala Cys Lys Pro
C17H31N5O5S (417.20457960000005)
Ala Cys Pro Lys
C17H31N5O5S (417.20457960000005)
Ala Asp Gly Arg
Ala Asp Arg Gly
Ala Glu Ala Lys
Ala Gly Asp Arg
Ala Gly Arg Asp
Ala Ile Asn Thr
Ala Ile Gln Ser
Ala Ile Ser Gln
Ala Ile Thr Asn
Ala Lys Ala Glu
Ala Lys Cys Pro
C17H31N5O5S (417.20457960000005)
Ala Lys Glu Ala
Ala Lys Pro Cys
C17H31N5O5S (417.20457960000005)
Ala Leu Asn Thr
Ala Leu Gln Ser
Ala Leu Ser Gln
Ala Leu Thr Asn
Ala Asn Ile Thr
Ala Asn Leu Thr
Ala Asn Thr Ile
Ala Asn Thr Leu
Ala Pro Cys Lys
C17H31N5O5S (417.20457960000005)
Ala Pro Lys Cys
C17H31N5O5S (417.20457960000005)
Ala Gln Ile Ser
Ala Gln Leu Ser
Ala Gln Ser Ile
Ala Gln Ser Leu
Ala Gln Thr Val
Ala Gln Val Thr
Ala Arg Asp Gly
Ala Arg Gly Asp
Ala Ser Ile Gln
Ala Ser Leu Gln
Ala Ser Gln Ile
Ala Ser Gln Leu
Ala Thr Ile Asn
Ala Thr Leu Asn
Ala Thr Asn Ile
Ala Thr Asn Leu
Ala Thr Gln Val
Ala Thr Val Gln
Ala Val Gln Thr
Ala Val Thr Gln
Ala Trp Ala Ala
C20H27N5O5 (417.20120920000005)
Cys Ala Lys Pro
C17H31N5O5S (417.20457960000005)
Cys Ala Pro Lys
C17H31N5O5S (417.20457960000005)
Cys Lys Ala Pro
C17H31N5O5S (417.20457960000005)
Cys Lys Pro Ala
C17H31N5O5S (417.20457960000005)
Cys Pro Ala Lys
C17H31N5O5S (417.20457960000005)
Cys Pro Lys Ala
C17H31N5O5S (417.20457960000005)
Asp Ala Gly Arg
Asp Ala Arg Gly
Asp Gly Ala Arg
Asp Gly Lys Val
Asp Gly Arg Ala
Asp Gly Val Lys
Asp Lys Gly Val
Asp Lys Val Gly
Asp Arg Ala Gly
Asp Arg Gly Ala
Asp Val Gly Lys
Asp Val Lys Gly
Glu Ala Ala Lys
Glu Ala Lys Ala
Glu Gly Gly Arg
Glu Gly Arg Gly
Glu Lys Ala Ala
Glu Arg Gly Gly
Gly Ala Asp Arg
Gly Ala Arg Asp
Gly Asp Ala Arg
Gly Asp Lys Val
Gly Asp Arg Ala
Gly Asp Val Lys
Gly Glu Gly Arg
Gly Glu Arg Gly
Gly Gly Glu Arg
Gly Gly Arg Glu
Gly Gly Val Trp
C20H27N5O5 (417.20120920000005)
Gly Gly Trp Val
C20H27N5O5 (417.20120920000005)
Gly Ile Gln Thr
Gly Ile Thr Gln
Gly Lys Asp Val
Gly Lys Val Asp
Gly Leu Gln Thr
Gly Leu Thr Gln
Gly Gln Ile Thr
Gly Gln Leu Thr
Gly Gln Thr Ile
Gly Gln Thr Leu
Gly Arg Ala Asp
Gly Arg Asp Ala
Gly Arg Glu Gly
Gly Arg Gly Glu
Gly Thr Ile Gln
Gly Thr Leu Gln
Gly Thr Gln Ile
Gly Thr Gln Leu
Gly Val Asp Lys
Gly Val Gly Trp
C20H27N5O5 (417.20120920000005)
Gly Val Lys Asp
Gly Val Trp Gly
C20H27N5O5 (417.20120920000005)
Gly Trp Gly Val
C20H27N5O5 (417.20120920000005)
Gly Trp Val Gly
C20H27N5O5 (417.20120920000005)
Ile Ala Asn Thr
Ile Ala Gln Ser
Ile Ala Ser Gln
Ile Ala Thr Asn
Ile Gly Gln Thr
Ile Gly Thr Gln
Ile Asn Ala Thr
Ile Asn Thr Ala
Ile Gln Ala Ser
Ile Gln Gly Thr
Ile Gln Ser Ala
Ile Gln Thr Gly
Ile Ser Ala Gln
Ile Ser Gln Ala
Ile Thr Ala Asn
Ile Thr Gly Gln
Ile Thr Asn Ala
Ile Thr Gln Gly
Lys Ala Ala Glu
Lys Ala Cys Pro
C17H31N5O5S (417.20457960000005)
Lys Ala Glu Ala
Lys Ala Pro Cys
C17H31N5O5S (417.20457960000005)
Lys Cys Ala Pro
C17H31N5O5S (417.20457960000005)
Lys Cys Pro Ala
C17H31N5O5S (417.20457960000005)
Lys Asp Gly Val
Lys Asp Val Gly
Lys Glu Ala Ala
Lys Gly Asp Val
Lys Gly Val Asp
Lys Pro Ala Cys
C17H31N5O5S (417.20457960000005)
Lys Pro Cys Ala
C17H31N5O5S (417.20457960000005)
Lys Pro Ser Ser
Lys Ser Pro Ser
Lys Ser Ser Pro
Lys Val Asp Gly
Lys Val Gly Asp
Leu Ala Asn Thr
Leu Ala Gln Ser
Leu Ala Ser Gln
Leu Ala Thr Asn
Leu Gly Gln Thr
Leu Gly Thr Gln
Leu Asn Ala Thr
Leu Asn Thr Ala
Leu Gln Ala Ser
Leu Gln Gly Thr
Leu Gln Ser Ala
Leu Gln Thr Gly
Leu Ser Ala Gln
Leu Ser Gln Ala
Leu Thr Ala Asn
Leu Thr Gly Gln
Leu Thr Asn Ala
Leu Thr Gln Gly
Asn Ala Ile Thr
Asn Ala Leu Thr
Asn Ala Thr Ile
Asn Ala Thr Leu
Asn Ile Ala Thr
Asn Ile Thr Ala
Asn Leu Ala Thr
Asn Leu Thr Ala
Asn Ser Val Val
Asn Thr Ala Ile
Asn Thr Ala Leu
Asn Thr Ile Ala
Asn Thr Leu Ala
Asn Val Ser Val
Asn Val Val Ser
Pro Ala Cys Lys
C17H31N5O5S (417.20457960000005)
Pro Ala Lys Cys
C17H31N5O5S (417.20457960000005)
Pro Cys Ala Lys
C17H31N5O5S (417.20457960000005)
Pro Cys Lys Ala
C17H31N5O5S (417.20457960000005)
Pro Lys Ala Cys
C17H31N5O5S (417.20457960000005)
Pro Lys Cys Ala
C17H31N5O5S (417.20457960000005)
Pro Lys Ser Ser
Pro Ser Lys Ser
Pro Ser Ser Lys
Gln Ala Ile Ser
Gln Ala Leu Ser
Gln Ala Ser Ile
Gln Ala Ser Leu
Gln Ala Thr Val
Gln Ala Val Thr
Gln Gly Ile Thr
Gln Gly Leu Thr
Gln Gly Thr Ile
Gln Gly Thr Leu
Gln Ile Ala Ser
Gln Ile Gly Thr
Gln Ile Ser Ala
Gln Ile Thr Gly
Gln Leu Ala Ser
Gln Leu Gly Thr
Gln Leu Ser Ala
Gln Leu Thr Gly
Gln Ser Ala Ile
Gln Ser Ala Leu
Gln Ser Ile Ala
Gln Ser Leu Ala
Gln Thr Ala Val
Gln Thr Gly Ile
Gln Thr Gly Leu
Gln Thr Ile Gly
Gln Thr Leu Gly
Gln Thr Val Ala
Gln Val Ala Thr
Gln Val Thr Ala
Arg Ala Asp Gly
Arg Ala Gly Asp
Arg Asp Ala Gly
Arg Asp Gly Ala
Arg Glu Gly Gly
Arg Gly Ala Asp
Arg Gly Asp Ala
Arg Gly Glu Gly
Arg Gly Gly Glu
Ser Ala Ile Gln
Ser Ala Leu Gln
Ser Ala Gln Ile
Ser Ala Gln Leu
Ser Ile Ala Gln
Ser Ile Gln Ala
Ser Lys Pro Ser
Ser Lys Ser Pro
Ser Leu Ala Gln
Ser Leu Gln Ala
Ser Asn Val Val
Ser Pro Lys Ser
Ser Pro Ser Lys
Ser Gln Ala Ile
Ser Gln Ala Leu
Ser Gln Ile Ala
Ser Gln Leu Ala
Ser Ser Lys Pro
Ser Ser Pro Lys
Ser Val Asn Val
Ser Val Val Asn
Thr Ala Ile Asn
Thr Ala Leu Asn
Thr Ala Asn Ile
Thr Ala Asn Leu
Thr Ala Gln Val
Thr Ala Val Gln
Thr Gly Ile Gln
Thr Gly Leu Gln
Thr Gly Gln Ile
Thr Gly Gln Leu
Thr Ile Ala Asn
Thr Ile Gly Gln
Thr Ile Asn Ala
Thr Ile Gln Gly
Thr Leu Ala Asn
Thr Leu Gly Gln
Thr Leu Asn Ala
Thr Leu Gln Gly
Thr Asn Ala Ile
Thr Asn Ala Leu
Thr Asn Ile Ala
Thr Asn Leu Ala
Thr Gln Ala Val
Thr Gln Gly Ile
Thr Gln Gly Leu
Thr Gln Ile Gly
Thr Gln Leu Gly
Thr Gln Val Ala
Thr Val Ala Gln
Thr Val Gln Ala
Val Ala Gln Thr
Val Ala Thr Gln
Val Asp Gly Lys
Val Asp Lys Gly
Val Gly Asp Lys
Val Gly Gly Trp
C20H27N5O5 (417.20120920000005)
Val Gly Lys Asp
Val Gly Trp Gly
C20H27N5O5 (417.20120920000005)
Val Lys Asp Gly
Val Lys Gly Asp
Val Asn Ser Val
Val Asn Val Ser
Val Gln Ala Thr
Val Gln Thr Ala
Val Ser Asn Val
Val Ser Val Asn
Val Thr Ala Gln
Val Thr Gln Ala
Val Val Asn Ser
Val Val Ser Asn
Val Trp Gly Gly
C20H27N5O5 (417.20120920000005)
Trp Ala Ala Ala
C20H27N5O5 (417.20120920000005)
Trp Gly Gly Val
C20H27N5O5 (417.20120920000005)
Trp Gly Val Gly
C20H27N5O5 (417.20120920000005)
Trp Val Gly Gly
C20H27N5O5 (417.20120920000005)
Cinepazide
C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
3-Pyridinecarboxaldehyde, 5-ethenyl-4-[4-fluoro-2-(phenylmethoxy)phenyl]-2,6-bis(1-methylethyl)-
(R)-α,α-Bis(3,5-dimethylphenyl)-2-pyrrolidineMethanol triMethylsilyl ether hydrochloride 97
C24H36ClNOSi (417.22545560000003)
4-Nitrophenyl phosphate bis(cyclohexylammonium) salt
(S)-2-(((3R,4R)-4-(3-Hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)methyl)-3-phenylpropanoic acid methyl ester hydrochloride
cyclohexanamine,(3-nitrophenyl) dihydrogen phosphate
GSK-J4
Benzenepropanoic acid, 4,4-(phenylimino)bis-,1,1-dimethyl ester
C26H27NO4 (417.19399820000007)
6-Chloro-1-methyl-2,4-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole
C21H30B2ClNO4 (417.2049350000001)
(5-acetamido-3,4-diacetyloxy-6-pentoxyoxan-2-yl)methyl acetate
C19H31NO9 (417.19987160000005)
TEGASEROD MALEATE
C20H27N5O5 (417.20120920000005)
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist Tegaserod maleate (SDZ-HTF-919) is an orally active serotonin receptor 4 (HTR4; 5-HT4R) agonist and a 5-HT2B receptor antagonist. Tegaserod maleate has pKis of 7.5, 8.4 and 7.0 for human recombinant 5-HT2A, 5-HT2B and 5-HT2C receptors, respectively. Tegaserod maleate causes tumor cell apoptosis, blunts PI3K/Akt/mTOR signaling and decreases S6 phosphorylation. Tegaserod maleate has anti-tumor activity and has the potential for irritable bowel syndrome (IBS) research[1][2][3].
Naphthalen-1-yl-(5-naphthalen-1-yl-1-pentylpyrrol-3-yl)methanone
N-[6-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c][1]benzopyran-3-yl]hex-4-ynyl]methanesulfonamide
C23H31NO4S (417.19736860000006)
methyl [(1E,5R)-5-{(3S)-3-[(2E,4E)-2,5-dimethylocta-2,4-dienoyl]-2,4-dioxo-3,4-dihydro-2H-pyran-6-yl}hexylidene]carbamate
(2S)-5-[[(2S)-6-amino-1-[[(1R)-1-carboxyethyl]amino]-1-oxohexan-2-yl]amino]-2-[[(2S)-2-aminopropanoyl]amino]-5-oxopentanoic acid
beta-Aminoarteether maleate
C19H31NO9 (417.19987160000005)
D009676 - Noxae > D016877 - Oxidants > D010545 - Peroxides
methyl [(1E,5R)-5-{3-[(2E,4E)-2,5-dimethylocta-2,4-dienoyl]-4-hydroxy-2-oxo-2H-pyran-6-yl}hex-1-en-1-yl]carbamate
7-(4-(Furan-2-ylmethyl)piperazin-1-yl)-2-(3-methoxyphenyl)-5,6-dimethylpyrazolo[1,5-a]pyrimidine
N-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylmethanesulfonamide
C17H31N5O5S (417.20457960000005)
N-[[(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylmethanesulfonamide
C17H31N5O5S (417.20457960000005)
N-[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylmethanesulfonamide
C17H31N5O5S (417.20457960000005)
N-[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylmethanesulfonamide
C17H31N5O5S (417.20457960000005)
N-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylmethanesulfonamide
C17H31N5O5S (417.20457960000005)
N-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylmethanesulfonamide
C17H31N5O5S (417.20457960000005)
N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylmethanesulfonamide
C17H31N5O5S (417.20457960000005)
N-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylmethanesulfonamide
C17H31N5O5S (417.20457960000005)
N-[[(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylmethanesulfonamide
C17H31N5O5S (417.20457960000005)
Asp-Gln-Arg
A tripeptide composed of L-aspartic acid, L-glutamine and L-arginine joined in sequence by peptide linkages.
3-[1-[Oxo-(1-phenylcyclopentyl)methyl]-4-piperidinyl]-5-phenyl-1,3,4-oxadiazol-2-one
C25H27N3O3 (417.20523120000007)
(4R)-2-[4-(3-hydroxypropoxy)phenyl]-N-[2-(4-morpholinyl)ethyl]-4-prop-2-enyl-5H-oxazole-4-carboxamide
N-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylmethanesulfonamide
C17H31N5O5S (417.20457960000005)
2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide
N-[[(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylmethanesulfonamide
C17H31N5O5S (417.20457960000005)
2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide
(6S,7S,8S)-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-4-[oxo(2-pyridinyl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
C25H27N3O3 (417.20523120000007)
N-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylmethanesulfonamide
C17H31N5O5S (417.20457960000005)
N-[[(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylmethanesulfonamide
C17H31N5O5S (417.20457960000005)
N-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylmethanesulfonamide
C17H31N5O5S (417.20457960000005)
N-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylmethanesulfonamide
C17H31N5O5S (417.20457960000005)
N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylmethanesulfonamide
C17H31N5O5S (417.20457960000005)
N-cyclohexyl-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[(4-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
N-cyclohexyl-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[(4-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
N-cyclohexyl-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[(4-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(1S,3S,4aS,9aR)-6-[[(cyclopentylamino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
2-[(1S,3R,4aS,9aR)-6-[[(cyclopentylamino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
2-[(1S,3R,4aR,9aS)-6-[[(cyclopentylamino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
(6R,7R,8S)-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-4-[oxo(2-pyridinyl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
C25H27N3O3 (417.20523120000007)
(6R,7S,8S)-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-4-[oxo(2-pyridinyl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
C25H27N3O3 (417.20523120000007)
N-cyclohexyl-2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[(4-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
N-cyclohexyl-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[(4-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
N-cyclohexyl-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[(4-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
N-cyclohexyl-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[(4-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
N-cyclohexyl-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[(4-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(1R,3S,4aR,9aS)-6-[[(cyclopentylamino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
2-[(1R,3R,4aS,9aR)-6-[[(cyclopentylamino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
2-[(1S,3S,4aR,9aS)-6-[[(cyclopentylamino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
2-[(1R,3S,4aS,9aR)-6-[[(cyclopentylamino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
(6S,7R,8R)-7-[4-(1-cyclopentenyl)phenyl]-8-(hydroxymethyl)-4-[1-oxo-2-(3-pyridinyl)ethyl]-1,4-diazabicyclo[4.2.0]octan-2-one
C25H27N3O3 (417.20523120000007)
(6R,7S,8R)-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-4-[oxo(2-pyridinyl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
C25H27N3O3 (417.20523120000007)
(6S,7S,8R)-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-4-[oxo(2-pyridinyl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
C25H27N3O3 (417.20523120000007)
(6S,7R,8S)-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-4-[oxo(2-pyridinyl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
C25H27N3O3 (417.20523120000007)
(6R,7R,8R)-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-4-[oxo(2-pyridinyl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
C25H27N3O3 (417.20523120000007)
(6S,7R,8R)-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-4-[oxo(2-pyridinyl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
C25H27N3O3 (417.20523120000007)
2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentylhydrazinecarboximidamide (2Z)-but-2-enedioic acid
C20H27N5O5 (417.20120920000005)
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists
4-[3-(3-methyl-1,3-benzothiazol-2(3H)-ylidene)prop-1-en-1-yl]-1-[3-(trimethylammonio)propyl]quinolinium
C26H31N3S+2 (417.22385660000003)
4-(6-ethoxypyrazolo[1,5-b]pyridazin-3-yl)-N-[3-(morpholin-4-yl)phenyl]pyrimidin-2-amine
2-N-[(1R)-1-[4-(4-methoxyphenoxy)phenyl]ethyl]-2-N-methylpyrimido[4,5-d]pyrimidine-2,5,7-triamine
2-(2-methylindol-1-yl)-1-[(2S)-2-(piperidine-1-carbonyl)-2,3-dihydro-1,4-benzoxazin-4-yl]ethanone
C25H27N3O3 (417.20523120000007)
(4R,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid
RS504393
C25H27N3O3 (417.20523120000007)
Ansofaxine hydrochloride
Ansofaxine hydrochloride (LY03005; LPM570065) is a triple reuptake inhibitor; inhibits serotonin, dopamine and norepinephrine reuptake with IC50 values of 723, 491 and 763 nM, respectively.
n-[(1e,5r)-5-{5-[(2e,4e)-2,5-dimethylocta-2,4-dienoyl]-4-hydroxy-6-oxopyran-2-yl}hex-1-en-1-yl]methoxycarboximidic acid
4-methoxy-3-methyl-5-[(4e)-3-methyl-11-(4-methyl-5-oxooxolan-2-yl)-5-oxa-10-azatricyclo[8.3.0.0²,⁶]tridecan-4-ylidene]furan-2-one
n-[(1e,5r)-5-{5-[(2e,4e)-2,5-dimethylocta-2,4-dienoyl]-6-hydroxy-4-oxopyran-2-yl}hex-1-en-1-yl]methoxycarboximidic acid
3,5,7-trihydroxy-6-(3-oxotetradec-4-en-1-yl)-1h-isoindole-4-carboxylic acid
7-(4,5-dimethoxy-2-methylnaphthalen-1-yl)-4,8-dimethoxy-1,3-dimethylisoquinoline
C26H27NO4 (417.19399820000007)
11-{[1-carboxy-2-(4-hydroxyphenyl)ethyl]-c-hydroxycarbonimidoyl}-7,9-dimethylundeca-8,10-dienoic acid
4-methoxy-3-methyl-5-[3-methyl-11-(4-methyl-5-oxooxolan-2-yl)-5-oxa-10-azatricyclo[8.3.0.0²,⁶]tridecan-4-ylidene]furan-2-one
4-methoxy-3-methyl-5-[(1s,2r,3s,4z)-3-methyl-11-[(2s,4s)-4-methyl-5-oxooxolan-2-yl]-5-oxa-10-azatricyclo[8.3.0.0²,⁶]tridecan-4-ylidene]furan-2-one
n-{5-[5-(2,5-dimethylocta-2,4-dienoyl)-4-hydroxy-6-oxopyran-2-yl]hex-1-en-1-yl}methoxycarboximidic acid
(7r,8e,10e)-11-{[1-carboxy-2-(4-hydroxyphenyl)ethyl]-c-hydroxycarbonimidoyl}-7,9-dimethylundeca-8,10-dienoic acid
4-methoxy-3-methyl-5-[(1s,2r,3s,4e,6r,11s)-3-methyl-11-[(2s,4s)-4-methyl-5-oxooxolan-2-yl]-5-oxa-10-azatricyclo[8.3.0.0²,⁶]tridecan-4-ylidene]furan-2-one
3,5,7-trihydroxy-6-[(4e)-3-oxotetradec-4-en-1-yl]-1h-isoindole-4-carboxylic acid
5-(4,5-dimethoxy-2-methylnaphthalen-1-yl)-6,8-dimethoxy-1,3-dimethylisoquinoline
C26H27NO4 (417.19399820000007)